+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Evaluation of left ventricular function in asymptomatic children about to undergo anthracycline-based chemotherapy for acute leukemia: an outcome study



Evaluation of left ventricular function in asymptomatic children about to undergo anthracycline-based chemotherapy for acute leukemia: an outcome study



Journal of Pediatric Hematology/Oncology 23(7): 420-423



Cardiac toxicity is a well-recognized potential complication of anthracycline use. Children treated with anthracyclines undergo several cardiac screening procedures before therapy, but the usefulness of these pretherapy cardiac studies has never been evaluated. The authors examined whether induction chemotherapy in patients with high-risk acute lymphoblastic leukemia (ALL) was altered based on a pretherapy left ventricular shortening fraction (SF). Medical records of 134 children registered on treatment protocols of the Pediatric Oncology Group for high-risk B-precursor and T-cell ALL between 1987 and 1998 were reviewed. Demographic information consisting of age at diagnosis, sex, and past cardiac history was collected, as were the results of all echocardiographic evaluations for SF and actions taken based on these evaluations. The outcome measured was whether any changes were made in induction therapy based on initial SF. In addition, secondary SF results obtained at the cumulative anthracycline dose range of 90 to 150 mg/m2 were studied to determine whether modifications of future chemotherapy were made after this limited exposure. Three of 128 children (2.3%) without a previous cardiac history had an initial SF on their pretherapy echocardiogram that prompted additional evaluation but no change in therapy. A secondary analysis of SF in 85 children who completed anthracycline doses of 90 to 150 mg/m2 was performed. There were three (3.5%) with abnormal study results who were evaluated further. Again, no changes were made in the anthracycline doses based on these findings. No cardiac dysfunction occurred among these six patients during later follow-up. In the absence of a previous cardiac history or signs and symptoms or cardiac disease, pretherapy evaluation of left ventricular function may not be indicated in children about to undergo anthracycline-based treatment of acute leukemia. The timing of initiation of cardiac evaluation remains unclear, but these results suggest that even at a cumulative dose of 90 to 150 mg/m2, studies to determine left ventricular function do not yield data sufficient to warrant a change in the clinical management of these patients.

(PDF emailed within 1 workday: $29.90)

Accession: 046010927

Download citation: RISBibTeXText

PMID: 11878575


Related references

Evaluation of Left Ventricular Function in Asymptomatic Children About to Undergo Anthracycline-Based Chemotherapy for Acute Leukemia: An Outcome Study. Journal of Pediatric Hematology/Oncology 23(7): 420-423, 2001

Noninvasive evaluation of chronic cumulative and acute cardiotoxicity induced by anthracycline in children with acute leukemia. Assessment of mainly left ventricular contractile state by M mode echocardiography. Nihon Ika Daigaku Zasshi 61(3): 209-219, 1994

Recovery of left ventricular function following discontinuation of anthracycline chemotherapy in children. Pediatrics 68(1): 67-72, 1981

Outcome of Patients with Acute Promyelocytic Leukemia Failing to Treatment with All-Trans Retinoic Acid and Anthracycline-Based Chemotherapy. Blood 100(11): Abstract No 1331, November 16, 2002

Left ventricular systolic function in HER2/neu negative breast cancer patients treated with anthracycline chemotherapy: a comparative analysis of left ventricular ejection fraction and myocardial strain imaging over 12 months. European Journal of Cancer 49(16): 3396-3403, 2013

The role of N-terminal pro-brain natriuretic peptide as marker of left ventricular dysfunction in children with acute lymphoblastic leukemia undergoing anthracycline therapy. 2006

The influence of premature ventricular contractions on left ventricular function in asymptomatic children without structural heart disease: an echocardiographic evaluation. International Journal of Cardiovascular Imaging 19(4): 295-299, 2003

Should patients with asymptomatic severe mitral regurgitation with good left ventricular function undergo surgical repair?. Interactive Cardiovascular and Thoracic Surgery 10(2): 299-305, 2010

Left ventricular diastolic function after anthracycline chemotherapy in childhood: relation with systolic function, symptoms, and pathophysiology. British Heart Journal 73(4): 340-350, 1995

Left ventricular systolic and diastolic function after anthracycline chemotherapy in childhood. Clinical Cardiology 24(10): 663-669, 2001

Monitoring left ventricular function in adults receiving anthracycline-containing chemotherapy. European Journal of Heart Failure 9(4): 409-414, 2006

Altered left ventricular longitudinal diastolic function correlates with reduced systolic function immediately after anthracycline chemotherapy. European Heart Journal Cardiovascular Imaging 14(3): 228-234, 2014

Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention. Leukemia 21(3): 446-452, 2007

The Tei index identifies a differential effect on left and right ventricular function with low-dose anthracycline chemotherapy. Journal of the American Society of Echocardiography 19(2): 206-210, 2006

Early detection of anthracycline induced cardiotoxicity in asymptomatic patients with normal left ventricular systolic function: autonomic versus echocardiographic variables. Heart 81(4): 419-423, 1999